SEARCH

SEARCH BY CITATION

References

  • 1
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 3
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al.; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 4
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al.; Virahep-C Study Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470477.
  • 5
    Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. HEPATOLOGY 2004; 39: 17021708.
  • 6
    Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 22652271. Erratum in: N Engl J Med 2004; 351: 1268.
  • 7
    Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. HEPATOLOGY 2005; 41: 275279.
  • 8
    Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: A population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701708.
  • 9
    Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006; 62: 710714.
  • 10
    Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. HEPATOLOGY 1999; 30: 787793.
  • 11
    Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000; 119: 13851396.
  • 12
    Shiffman M, Pockros PJ, Reddy RK, Wright TL, Reindollar R, Fried MW, et al. and the pegylated interferon alfa-2a Clinical Study Group. A controlled, randomized, multicenter, descending dose, phase II trial of pegylated interferon alfa-2a (PEG) vs standard interferon alfa-2a (IFN) for treatment of chronic hepatitis C [abstract]. Gastroenterology 1999; 116: L418.
  • 13
    Heathcote EJ, Shiffman ML, Cooksley G, Dusheiko GM, Lee SS, Balart L, et al. Multinational evaluation of the efficacy and safety of once weekly peginterferon a2A in patients with chronic hepatitis C with compensated cirrhosis [abstract]. HEPATOLOGY 1999; 30: 316A.
  • 14
    McHutchison JG, Poynard T, Gordon SC, Dienstag J, Morgan T, Yao R, et al. The impact of race on response to anti-viral therapy in patients with chronic hepatitis C [abstract]. HEPATOLOGY 1999; 30: 302A.
  • 15
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556562.
  • 16
    Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. HEPATOLOGY 2003; 37: 13431350.
  • 17
    Layden-Almer JE, Layden TJ. Viral kinetics in hepatitis C virus: special patient populations. Semin Liver Dis 2003; 23(Suppl 1): 2933.
  • 18
    Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004; 432: 922924.
  • 19
    Jacobson I, Brown RS Jr, McCone J, Black M, Albert C, Dragutsky MS, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with HCV genotype 1. HEPATOLOGY 2007; 46. DOI: 10.1002/hep.21670.